Terms: = Prostate cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC
122 results:
1. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
2. Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.
Papadopoulou E; Rigas G; Fountzilas E; Boutis A; Giassas S; Mitsimponas N; Daliani D; Ziogas DC; Liontos M; Ramfidis V; Christophilakis C; Matthaios D; Floros T; Florou-Chatzigiannidou C; Agiannitopoulos K; Meintani A; Tsantikidi A; Katseli A; Potska K; Tsaousis G; Metaxa-Mariatou V; Nasioulas G
JCO Precis Oncol; 2024 Jan; 8():e2300332. PubMed ID: 38271656
[TBL] [Abstract] [Full Text] [Related]
3. New Insights into Lynch Syndrome: A Narrative Review.
Ene CV; Bulai CTLA; Geavlete P; Popescu RI; Vacaroiu IA; Georgescu DE; Isaconi IV; Munteanu MDLA; Ene CD; Militaru A; Geavlete B; Multescu R
Chirurgia (Bucur); 2023 Dec; 118(6):584-595. PubMed ID: 38228591
[TBL] [Abstract] [Full Text] [Related]
4. Invasive stratified mucin-producing carcinoma of the colorectum: expanding the morphologic spectrum of large bowel cancer.
Auld FM; Moyana TN
Diagn Pathol; 2023 Oct; 18(1):113. PubMed ID: 37853375
[TBL] [Abstract] [Full Text] [Related]
5. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
[No Abstract] [Full Text] [Related]
6. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling.
Özdemir Z; Çevik E; Öksüzoğlu ÖBÇ; Doğan M; Ateş Ö; Esin E; Bilgetekin İ; Demirci U; Köseoğlu Ç; Topal A; Karadurmuş N; Erdem HB; Bahsi T
Mutat Res; 2023; 827():111831. PubMed ID: 37453313
[TBL] [Abstract] [Full Text] [Related]
7. Mismatch repair gene germline mutations in patients with prostate cancer.
Fang B; Wei Y; Pan J; Zhang T; Ye D; Zhu Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):133-138. PubMed ID: 37283096
[TBL] [Abstract] [Full Text] [Related]
8. mlh1 Loss in Primary prostate cancer.
Nourmohammadi Abadchi S; Sena LA; Antonarakis ES; Pritchard CC; Eshleman JR; Konnick EQ; Salipante SJ; Shenderov E; Lotan TL
JCO Precis Oncol; 2023 May; 7():e2200611. PubMed ID: 37196219
[TBL] [Abstract] [Full Text] [Related]
9. Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome.
Cerrato C; Pandolfo SD; Autorino R; Panunzio A; Tafuri A; Porcaro AB; Veccia A; De Marco V; Cerruto MA; Antonelli A; Derweesh IH; Maresma MCM
World J Urol; 2023 Jul; 41(7):1741-1749. PubMed ID: 36964236
[TBL] [Abstract] [Full Text] [Related]
10. Whole-exome Sequencing of Nigerian prostate Tumors from the prostate cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA; Kaninjing ET; Adeniji KA; Jibrin P; Obafunwa JO; Ogo CN; Mohammed F; Popoola A; Fatiregun OA; Oluwole OP; Karanam B; Elhussin I; Ambs S; Tang W; Davis M; Polak P; Campbell MJ; Brignole KR; Rotimi SO; Dean-Colomb W; Odedina FT; Martin DN; Yates C
Cancer Res Commun; 2022 Sep; 2(9):1005-1016. PubMed ID: 36922933
[TBL] [Abstract] [Full Text] [Related]
11. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
Marino F; Totaro A; Gandi C; Bientinesi R; Moretto S; Gavi F; Pierconti F; Iacovelli R; Bassi P; Sacco E
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):655-664. PubMed ID: 36434163
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in prostate cancer Patients.
Zhang D; Xu X; Wei Y; Chen X; Li G; Lu Z; Zhang X; Ren X; Wang S; Qin C
Cancer Control; 2022; 29():10732748221129451. PubMed ID: 36283420
[TBL] [Abstract] [Full Text] [Related]
13. Germline Variant Spectrum Among African American Men Undergoing prostate cancer Germline Testing: Need for Equity in Genetic Testing.
Giri VN; Hartman R; Pritzlaff M; Horton C; Keith SW
JCO Precis Oncol; 2022 May; 6(1):e2200234. PubMed ID: 35666082
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with prostate cancer Risk in Polish Men.
Heise M; Jarzemski P; Nowak D; Bąk A; Junkiert-Czarnecka A; Pilarska-Deltow M; Borysiak M; Pilarska B; Haus O
Cancer Control; 2022; 29():10732748211062342. PubMed ID: 35638715
[No Abstract] [Full Text] [Related]
15. Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and TCGA cohorts.
Li Z; Jia Y; Zhu H; Yuan H; Xing X; Xin Y; Ma T; Pang F; Zhang Y; Hu Y; Jia S; Ji J
Int J Cancer; 2022 Oct; 151(8):1382-1393. PubMed ID: 35567574
[TBL] [Abstract] [Full Text] [Related]
16. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
[TBL] [Abstract] [Full Text] [Related]
17. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
Bancroft EK; Page EC; Brook MN; Thomas S; Taylor N; Pope J; McHugh J; Jones AB; Karlsson Q; Merson S; Ong KR; Hoffman J; Huber C; Maehle L; Grindedal EM; Stormorken A; Evans DG; Rothwell J; Lalloo F; Brady AF; Bartlett M; Snape K; Hanson H; James P; McKinley J; Mascarenhas L; Syngal S; Ukaegbu C; Side L; Thomas T; Barwell J; Teixeira MR; Izatt L; Suri M; Macrae FA; Poplawski N; Chen-Shtoyerman R; Ahmed M; Musgrave H; Nicolai N; Greenhalgh L; Brewer C; Pachter N; Spigelman AD; Azzabi A; Helfand BT; Halliday D; Buys S; Ramon Y Cajal T; Donaldson A; Cooney KA; Harris M; McGrath J; Davidson R; Taylor A; Cooke P; Myhill K; Hogben M; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Dias A; Dudderidge T; Eccles DM; Green K; Eyfjord J; Falconer A; Foster CS; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Lilja H; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra AV; Moynihan C; Ni Raghallaigh H; Rennert G; Collier R; ; Offman J; Kote-Jarai Z; Eeles RA
Lancet Oncol; 2021 Nov; 22(11):1618-1631. PubMed ID: 34678156
[TBL] [Abstract] [Full Text] [Related]
18. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract] [Full Text] [Related]
19. Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
Wei J; Yang W; Shi Z; Lu L; Wang Q; Resurreccion WK; Engelmann V; Zheng SL; Hulick PJ; Cooney KA; Isaacs WB; Helfand BT; Lu J; Xu J
Prostate; 2021 Sep; 81(13):1002-1008. PubMed ID: 34254341
[TBL] [Abstract] [Full Text] [Related]
20. Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade.
Sena LA; Salles DC; Engle EL; Zhu Q; Tukachinsky H; Lotan TL; Antonarakis ES
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34140335
[TBL] [Abstract] [Full Text] [Related]
[Next]
